공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

흡연 중독 : 파이프라인 리뷰

Smoking Addiction - Pipeline Review, H2 2017

리서치사 Global Markets Direct
발행일 2017년 12월 상품 코드 363109
페이지 정보 영문 89 Pages
가격
US $ 2,000 ₩ 2,276,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,553,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,830,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


흡연 중독 : 파이프라인 리뷰 Smoking Addiction - Pipeline Review, H2 2017
발행일 : 2017년 12월 페이지 정보 : 영문 89 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

흡연 중독(Smoking Addiction) 치료제 개발 상황에 대해 분석했으며, 개발 단계, 약제 표적, 작용기서, 투여 경로 및 분자 종류별 분석, 치료제 개발에 참여하고 있는 기업 개요, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

흡연 중독 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

흡연 중독 : 기업에서 개발중인 치료제

흡연 중독 : 대학/기관에서 연구중인 치료제

흡연 중독 : 파이프라인 제품 개요

  • 임상 단계 제품
  • 초기 단계 제품
  • 개발 단계가 불명인 제품

흡연 중독 : 기업에서 개발중인 제품

흡연 중독 : 대학/기관에서 연구중인 제품

흡연 중독 치료제 개발에 참여하고 있는 기업

  • Aradigm Corporation
  • Arena Pharmaceuticals, Inc.
  • Astraea Therapeutics, LLC
  • Bioprojet SCR
  • Cerecor Inc.
  • CoMentis, Inc.
  • Embera NeuroTherapeutics, Inc.
  • Euthymics Bioscience, Inc.
  • Invion Limited
  • Johnson & Johnson
  • Marinus Pharmaceuticals, Inc.
  • NAL Pharmaceuticals Ltd.
  • Pfizer Inc.
  • Selecta Biosciences, Inc.
  • Zynerba Pharmaceuticals, Inc.

흡연 중독 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

흡연 중독 : 휴지중인 프로젝트

흡연 중독 : 개발이 중지된 제품

흡연 중독 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSM 16.07.25

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smoking Addiction - Pipeline Review, H2 2017, provides an overview of the Smoking Addiction (Central Nervous System) pipeline landscape.

Smoking is addictive, people experience an uncontrollable dependence on cigarettes, which on stopping will cause severe mental, emotional or physical reactions. People addicted to smoking develop tolerance to nicotine. Nicotine acts on acetylcholine receptors causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological functions of many brain systems. This causes structural and functional changes in the brains of smokers. Upon sudden nicotine withdrawal, the brain and other parts of the body get disturbed, leading to a condition called withdrawal syndrome. The body usually takes time to function in the absence of nicotine. Symptoms include anger, depression, weight gain headaches and dizziness. The effects of smoking withdrawal stem from the lack of nicotine that can be overcome by nicotine replacement therapies such as the use of nicotine patch or nicotine chewing gum.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smoking Addiction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Smoking Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smoking Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 7, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Smoking Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Smoking Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Smoking Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Smoking Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Smoking Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Smoking Addiction (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Smoking Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Smoking Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Smoking Addiction - Overview
    • Smoking Addiction - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Smoking Addiction - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Smoking Addiction - Companies Involved in Therapeutics Development
    • Aradigm Corp
    • AstraZeneca Plc
    • Axsome Therapeutics Inc
    • Bionex Pharmaceuticals LLC
    • Bioprojet SCR
    • CoMentis Inc
    • Embera NeuroTherapeutics Inc
    • Invion Ltd
    • Jeil Pharmaceutical Co Ltd
    • Johnson & Johnson
    • Lotus Pharmaceutical Co Ltd
    • NAL Pharmaceuticals Ltd
    • Pfizer Inc
    • Selecta Biosciences Inc
    • Sopharma AD
    • Zynerba Pharmaceuticals Inc
  • Smoking Addiction - Drug Profiles
    • (bupropion hydrochloride + dextromethorphan hydrobromide) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (metyrapone + oxazepam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AKR-214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amitifadine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-8529 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BP-1.4979 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Canquit - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cytisine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GTS-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JLP-1603 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-39393406 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nadolol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NFL-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nicotine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nicotine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nicotine bitartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06413367 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEL-070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Cannabinoid Receptor for Smoking Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Sodium Dependent Dopamine, Noradrenaline and Serotonin Transporters for Appetite Suppression and Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CHRN for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CHRNA3 and CHRNB4 for Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URB-694 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Smoking Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Smoking Addiction - Dormant Projects
  • Smoking Addiction - Discontinued Products
  • Smoking Addiction - Product Development Milestones
    • Featured News & Press Releases
      • May 11, 2017: Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention
      • Oct 20, 2016: OWC Pharmaceutical Research Completes Development of Its Medical Cannabis Sublingual Tablet
      • Nov 17, 2015: Invion Phase 2 Smoking Cessation Data: Results of Ongoing Analysis
      • Oct 05, 2015: Invion Successfully Completes Phase 2 Study of INV102 to Aid Smoking Cessation
      • Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation
      • Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation
      • Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation
      • Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform
      • Jan 29, 2014: FDA clears path for "Smoking Cessation" clinical trial of INV102 (nadolol)
      • Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial
      • Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL
      • Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs
      • Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint
      • Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation
      • Jan 12, 2012: Inverseon Focuses On Smoking Cessation As Initial Indication For INV102
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Smoking Addiction, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Smoking Addiction - Pipeline by Aradigm Corp, H2 2017
  • Smoking Addiction - Pipeline by AstraZeneca Plc, H2 2017
  • Smoking Addiction - Pipeline by Axsome Therapeutics Inc, H2 2017
  • Smoking Addiction - Pipeline by Bionex Pharmaceuticals LLC, H2 2017
  • Smoking Addiction - Pipeline by Bioprojet SCR, H2 2017
  • Smoking Addiction - Pipeline by CoMentis Inc, H2 2017
  • Smoking Addiction - Pipeline by Embera NeuroTherapeutics Inc, H2 2017
  • Smoking Addiction - Pipeline by Invion Ltd, H2 2017
  • Smoking Addiction - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
  • Smoking Addiction - Pipeline by Johnson & Johnson, H2 2017
  • Smoking Addiction - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017
  • Smoking Addiction - Pipeline by NAL Pharmaceuticals Ltd, H2 2017
  • Smoking Addiction - Pipeline by Pfizer Inc, H2 2017
  • Smoking Addiction - Pipeline by Selecta Biosciences Inc, H2 2017
  • Smoking Addiction - Pipeline by Sopharma AD, H2 2017
  • Smoking Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2017
  • Smoking Addiction - Dormant Projects, H2 2017
  • Smoking Addiction - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Smoking Addiction - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Smoking Addiction, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top
전화 문의
F A Q